PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
71.64
-2.03 (-2.76%)
Aug 20, 2026, 10:37 AM EDT - Market open
PTC Therapeutics Revenue
PTC Therapeutics had revenue of $360.52M in the quarter ending June 30, 2026, with 101.55% growth. This brings the company's revenue in the last twelve months to $1.01B, down -42.84% year-over-year. In the year 2025, PTC Therapeutics had annual revenue of $1.73B with 114.51% growth.
Revenue (ttm)
$1.01B
Revenue Growth
-42.84%
P/S Ratio
6.10
Revenue / Employee
$1,017,915
Employees
991
Market Cap
5.98B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.73B | 923.88M | 114.51% |
| Dec 31, 2024 | 806.78M | -131.04M | -13.97% |
| Dec 31, 2023 | 937.82M | 239.02M | 34.20% |
| Dec 31, 2022 | 698.80M | 160.21M | 29.75% |
| Dec 31, 2021 | 538.59M | 157.83M | 41.45% |
| Dec 31, 2020 | 380.77M | 73.79M | 24.04% |
| Dec 31, 2019 | 306.98M | 42.25M | 15.96% |
| Dec 31, 2018 | 264.73M | 70.34M | 36.19% |
| Dec 31, 2017 | 194.39M | 111.69M | 135.04% |
| Dec 31, 2016 | 82.71M | 45.94M | 124.95% |
| Dec 31, 2015 | 36.77M | 11.52M | 45.64% |
| Dec 31, 2014 | 25.25M | -9.45M | -27.24% |
| Dec 31, 2013 | 34.70M | 750.00K | 2.21% |
| Dec 31, 2012 | 33.95M | -71.47M | -67.80% |
| Dec 31, 2011 | 105.41M | 100.45M | 2,022.34% |
| Dec 31, 2005 | 4.97M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Caris Life Sciences | 989.61M |
| Mirum Pharmaceuticals | 618.07M |
| Travere Therapeutics | 591.33M |
| Ligand Pharmaceuticals | 290.54M |
| Xenon Pharmaceuticals | 7.50M |
| Dianthus Therapeutics | 1.90M |
PTCT News
- 3 days ago - PTC Therapeutics to acquire ST-920 from Sangamo Therapeutics - TheFly
- 3 days ago - PTC Therapeutics price target raised to $109 from $106 at Wells Fargo - TheFly
- 4 days ago - PTC Therapeutics price target raised to $122 from $120 at Barclays - TheFly
- 7 days ago - PTC Therapeutics Transcript: Investor update - Transcripts
- 7 days ago - PTC Therapeutics Press release: Investor update - Filings
- 7 days ago - PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program - PRNewsWire
- 20 days ago - PTC Therapeutics price target raised to $96 from $95 at BofA - TheFly
- 20 days ago - PTC Therapeutics price target raised to $104 from $93 at Morgan Stanley - TheFly